A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma

NCT05800366 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma
Lymphoma, Large B-Cell, Diffuse

Interventions

DRUG: Glofitamab
DRUG: Polatuzumab
DRUG: Rituximab
DRUG: Doxorubicin Hydrochloride
DRUG: Cyclophosphamide
DRUG: Prednisone

Sponsor

Jennifer Crombie, MD

Collaborators

[object Object]